Sequence: RGD motif (arginine–glycine–aspartate)
| Experiment Id | EXP002032 |
|---|---|
| Paper | Targeted OUM1/PTPRZ1 silencing and synergetic CDT/enhanced chemical therapy toward uveal melanoma ba |
| Peptide | RGD |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | MOF-PR 5–20 mg/kg (IV injection) |
| Rna Concentration | co-loaded with MOF |
| Mixing Ratio | |
| Formulation Format | metal–organic framework nanoparticle (MOF-PR) |
| Formulation Components | Mn@MOF + PEG + RGD peptide + siOUM1 + siPTPRZ1 ± cisplatin + ICG |
| Size Nm | 130.00 |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | BALB/c nude mice (OCM1a xenograft; pulmonary metastasis model) |
| Administration Route | intravenous (tail vein) |
| Output Type | tumor growth suppression / metastasis inhibition |
| Output Value | Significant tumor regression and complete inhibition of lung metastasis |
| Output Units | |
| Output Notes | In vivo RNA ISH confirms OUM1/PTPRZ1 knockdown; Ki-67 reduced; survival benefit implied |
| Toxicity Notes | No major organ toxicity; stable body weight |
| Curation Notes |